All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Oncomed Pharmaceuticals Inc., of Redwood City, Calif., said the FDA removed the partial clinical hold on enrollment in the firm's vantictumab (anti-Fzd7, OMP-18R5) phase I trials.
